Hoth Therapeutics: Stephanie Johns, chief scientific officer
Biopharma firm Hoth Therapeutics has appointed Stefanie Johns to the position of chief scientific officers. In the role, Johns will be charged with advancing the company’s drug pipeline through both preclinical and clinical stages.
Johns brings to the company experience in development across drug, biologic, medical devices, and in vitro diagnostic device products in US and global markets. Most recently she had been director of regulatory affairs at Enable Injections, where she led the global regulatory strategy for subcutaneous drug delivery device platforms.
People on the Move: September 2020 Clinical Ink: acquisition by GI Partners Florence Healthcare: Cooper Anderson, CFO Premier Research: Cassandra Matney, senior medical director Colorcon: Australia technical center Black Diamond Therapeutics: Fang Ni, chief business officer Endocrine Society: Richard Ross, Laureate Award for Outstanding Innovation Nanoform: Eric Peter, product manager Nanoform: Sergie Letser, product manager Aetion: Johnson & Johnson investment Hoth Therapeutics: Stephanie Johns, chief scientific officer